Loading...
Loading...
NERV| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 7.7K |
| Gross Profit | -7.7K |
| Operating Expense | 7,164.2K |
| Operating I/L | -7,171.9K |
| Other Income/Expense | -1,850.5K |
| Interest Income | 358.9K |
| Pretax | -9,022.5K |
| Income Tax Expense | -5,622.0K |
| Net Income/Loss | -9,022.5K |
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of product candidates for central nervous system diseases. Its primary focus is on roluperidone, a treatment for schizophrenia, and MIN-301, a neuregulin-1b1 protein for Parkinson's disease and other neurodegenerative disorders.
